Evidence map›Paper›PMID 40355839›Full record

ArticleMolecular medicine (Cambridge, Mass.)2025

QRICH1 regulates ATF6 transcription to affect pathological cardiac hypertrophy progression.

Lihui Zhang, Hongping Chen, Guangmei Zou, Wenjuan Jia, Haibin Dong, Chunxiao Wang, Hua Wang, Yugang Liu, Da Teng, Bowen Xu and 3 more

Abstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lihui Zhang *Medical College, Qingdao University, Qingdao, Shandong, China.
Hongping Chen *Department of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Guangmei ZouDepartment of Cardiac Surgery, Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China.
Wenjuan JiaDepartment of Cardiology, Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China.
Haibin DongDepartment of Cardiology, Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China.
Chunxiao WangDepartment of Cardiology, Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China.
Hua WangDepartment of Cardiology, Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China.
Yugang LiuDepartment of Cardiology, Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China.
Da TengMedical College, Qingdao University, Qingdao, Shandong, China.
Bowen XuMedical College, Qingdao University, Qingdao, Shandong, China.
Lin ZhongDepartment of Cardiology, Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China. yizun1971@126.com.
Lei GongDepartment of Cardiology, Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China. leigong27@163.com.
Jun YangDepartment of Cardiology, Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China. yangjyhd@qdu.edu.cn.

Funding

Natural Science Foundation of Shandong Province No. ZR2023QH348
6 · The paper itself

Abstract

backgroundMany studies have shown that pathological cardiac hypertrophy is associated with active endoplasmic reticulum (ER) stress. Glutamine-rich protein 1 (QRICH1), as a transcriptional regulator, belongs to the caspase recruitment domain (CARD)-containing gene family. QRICH1 has been shown to influence the outcomes of endoplasmic reticulum stress by regulating the transcription of proteostasis-related genes. In this study, we explored the role of QRICH1 in pathological cardiac hypertrophy.

methodsWe observed an increased expression of QRICH1 in the hearts of humans and mice with left ventricular hypertrophy (LVH). To assess the functional impact in this context, we employed gain- and loss-of-function approaches, using AAV9 injections to establish cardiac-specific QRICH1 knockdown or overexpression models in transverse aortic constriction (TAC) or isoproterenol (ISO)-induced cardiac hypertrophy.

resultsOur data indicated that cardiomyocyte-specific knockdown of QRICH1 alleviated the hypertrophic phenotype in response to TAC or ISO injection. However, overexpression of QRICH1 exacerbated cardiac hypertrophy, remodeling, dysfunction, cell apoptosis, and inflammatory responses. Mechanistically, we demonstrated that ATF6 was significantly enriched by QRICH1 in cardiomyocytes treated with ISO using RNA-seq combined with CUT&TAG analysis. ChIP-qPCR and luciferase assays further confirmed that ATF6 is a target gene of QRICH1 in cardiomyocytes under growth stimulation. Knockdown of QRICH1 in cardiomyocytes blocked ISO-mediated induction of ATF6, activation of mTORC1, and cellular growth. And all of the above was restored by the overexpression of ATF6.

conclusionsQRICH1 plays a pivotal role in cardiac hypertrophy by regulating ATF6, and QRICH1 may be a potential new therapeutic target for pathological cardiac hypertrophy.

Indexed as

Activating Transcription Factor 6CardiomegalyTranscription, GeneticAnimalsApoptosisDisease Models, AnimalDisease ProgressionEndoplasmic Reticulum StressGene Expression RegulationHumansHypertrophy, Left VentricularIsoproterenolMaleMiceMice, Inbred C57BLMyocytes, CardiacActivating Transcription Factor 6IsoproterenolCardiac remodelingEndoplasmic reticulum stressHeart failurePressure overload

Identifiers

PMID40355839
PMCPMC12070701

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.